Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic

AIMS: At the beginning of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there were no clinically-tested medications for the effective treatment of coronavirus disease. In this context, on 5 March 2020, the French Public Health Council issued several recommendations for t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lory, Pauline, Lombardi, Jeffrey, Lacroix, Clémence, Sanchez-Pena, Paola, Romani, Serena, Grandvuillemin, Aurélie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Masson SAS on behalf of Société française de pharmacologie et de thérapeutique. 2022
Materias:
Pharmacovigilance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712669/
https://www.ncbi.nlm.nih.gov/pubmed/35568573
http://dx.doi.org/10.1016/j.therap.2021.12.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712669/
https://www.ncbi.nlm.nih.gov/pubmed/35568573
http://dx.doi.org/10.1016/j.therap.2021.12.015

Ejemplares similares